FDA guidance documents

FDA guidance documents set out the US Food and Drug Administration's current thinking on a regulatory issue, from how to design a clinical trial to what a device submission should contain. They are not law. Under the agency's Good Guidance Practices regulation, 21 CFR 10.115, guidance documents "do not establish legally enforceable rights or responsibilities" and "do not legally bind the public or FDA," and each one must prominently state that it is nonbinding. A company may use a different approach, provided it meets the underlying statutes and regulations.

The regulation sorts guidance into two levels:

• Level 1 guidance covers initial interpretations of a statute or regulation, significant policy changes, complex scientific issues and highly controversial topics. FDA normally publishes it in draft with a Federal Register notice and invites comment before implementing it, then issues a final version.
• Level 2 guidance covers existing practices or minor changes. FDA posts it, implements it immediately and accepts comments at any time.

Guidance is still the most practical statement of what FDA reviewers expect, which is why regulatory affairs teams track it as closely as rules. Three features make it a horizon-scanning source in its own right. Draft guidance can circulate for a long time before it is finalized, so the draft is the early signal. Once a year, FDA publishes a list of possible topics for future guidance development or revision, a free forward look. And the agency's guidance database records draft or final status and flags documents open for comment.

For each relevant document, log whether it is draft or final, the comment deadline, the products it touches and the date you last reviewed it, and treat the final version of a draft as a new change. The EU counterpart for devices is covered under EU MDR, and the regulatory intelligence explainer shows where guidance tracking sits in the wider pipeline.

This entry is general information, not legal advice.